Abstract

Join this webinar to explore how pharma companies can navigate the evolving regulatory landscape and harness the full potential of AI technologies while staying ahead of FDA's cautious, risk-based approach to regulation.

New AI technologies hold tremendous potential for use in all areas of the pharma industry, but as the industry ventures into this uncharted territory, new regulatory considerations must be addressed. FDA Commissioner Robert Califf has communicated a desire to get ahead of regulating new disruptive technology and most anticipate that regulators will adopt a cautious yet risk-based approach. Alessandro Zannini, Director of Proposal and Product Management in Stevanato Group and Federico Scattolin, System Owner AI in Stevanato Group, will explore how pharma companies can navigate this evolving regulatory landscape in order to make the most of AI technologies.